Author

Xavier Calvet Calvo

TIME TRENDS AND EFFECTIVENESS OF BISMUTH TREATMENT FOR HELICOBACTER PYLORI INFECTION: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) DURING 2013-2021
TIME TRENDS AND EFFECTIVENESS OF BISMUTH TREATMENT FOR HELICOBACTER PYLORI INFECTION: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) DURING 2013-2021

Xavier Calvet Calvo  et al.

INMUNE-MEDIATED COLITIS IN A PACIENT WITH ULCERATIVE COLITIS IN THE CONTEXT OF STAGE IV PULMONARY NEOPLASM TREATED WITH PEMBROLIZUMAB
INMUNE-MEDIATED COLITIS IN A PACIENT WITH ULCERATIVE COLITIS IN THE CONTEXT OF STAGE IV PULMONARY NEOPLASM TREATED WITH PEMBROLIZUMAB

Xavier Calvet Calvo  et al.

REINDUCTION AND INTENSIFICATION STRATEGY WITH USTEKINUMAB IN IBD PATIENTS, A SINGLE CENTER REAL LIFE EXPERIENCE
REINDUCTION AND INTENSIFICATION STRATEGY WITH USTEKINUMAB IN IBD PATIENTS, A SINGLE CENTER REAL LIFE EXPERIENCE

Xavier Calvet Calvo  et al.

USEFULNESS OF THE MODIFIED PRENDOSCOPIC ROCKALL INDEX TO PREDICT OUTCOMES IN UPPER GASTROINTESTINAL BLEEDING DUE TO PEPTIC ULCER
USEFULNESS OF THE MODIFIED PRENDOSCOPIC ROCKALL INDEX TO PREDICT OUTCOMES IN UPPER GASTROINTESTINAL BLEEDING DUE TO PEPTIC ULCER

Xavier Calvet Calvo  et al.

EPIDEMIOLOGY AND CHANGES IN PHARMACOLOGIC TREATMENT OF PEDIATRIC INFLAMMATORY BOWEL DISEASE OVER 10 YEARS IN CATALONIA
EPIDEMIOLOGY AND CHANGES IN PHARMACOLOGIC TREATMENT OF PEDIATRIC INFLAMMATORY BOWEL DISEASE OVER 10 YEARS IN CATALONIA

Xavier Calvet Calvo  et al.

A RARE CAUSE OF LOWER GI BLEEDING: ISCHEMIC COLITIS DUE TO KAYEXALATE CRYSTALS
A RARE CAUSE OF LOWER GI BLEEDING: ISCHEMIC COLITIS DUE TO KAYEXALATE CRYSTALS

Xavier Calvet Calvo  et al.

COMMON VARIABLES SCORE IN PREDICTING THE OUTCOMES OF PATIENTS WITH ACUTE LOWER GASTROINTESTINAL BLEEDING: A DIAGNOSTIC ACCURACY STUDY
COMMON VARIABLES SCORE IN PREDICTING THE OUTCOMES OF PATIENTS WITH ACUTE LOWER GASTROINTESTINAL BLEEDING: A DIAGNOSTIC ACCURACY STUDY

Xavier Calvet Calvo  et al.

REAL-LIFE EXPERIENCE OF THE EFFICACY, SAFETY AND PHARMACOKINETIC DATA OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INACTIVE INFLAMMATORY BOWEL DISEASE PATIENTS. RESULTS FROM THE ENEIDA REGISTRY
REAL-LIFE EXPERIENCE OF THE EFFICACY, SAFETY AND PHARMACOKINETIC DATA OF SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB IN INACTIVE INFLAMMATORY BOWEL DISEASE PATIENTS. RESULTS FROM THE ENEIDA REGISTRY

Xavier Calvet Calvo  et al.

ECONOMIC IMPACT OF INFLAMATORY BOWEL DISEASE IN CATALONIA.A POPULATION-BASED ANALYSIS
ECONOMIC IMPACT OF INFLAMATORY BOWEL DISEASE IN CATALONIA.A POPULATION-BASED ANALYSIS

Xavier Calvet Calvo  et al.

USTEKINUMAB AND VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE IN CLINICAL PRACTICE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY
USTEKINUMAB AND VEDOLIZUMAB AS FIRST-LINE BIOLOGICAL THERAPY FOR INFLAMMATORY BOWEL DISEASE IN CLINICAL PRACTICE. A MULTICENTER STUDY BASED ON THE ENEIDA REGISTRY

Xavier Calvet Calvo  et al.

RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY
RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY

Xavier Calvet Calvo  et al.

ACCELERATED OR ESCALATED INDUCTION REGIMENS OF INFLIXIMAB FOR STEROID-REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS IN CLINICAL PRACTICE: DATA FORM THE ENEIDA REGISTRY
ACCELERATED OR ESCALATED INDUCTION REGIMENS OF INFLIXIMAB FOR STEROID-REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS IN CLINICAL PRACTICE: DATA FORM THE ENEIDA REGISTRY

Xavier Calvet Calvo  et al.

PREVALENCE OF UNDIAGNOSED INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH SPONDYLOARTHRITIS: EISER STUDY
PREVALENCE OF UNDIAGNOSED INFLAMMATORY BOWEL DISEASE IN PATIENTS WITH SPONDYLOARTHRITIS: EISER STUDY

Xavier Calvet Calvo  et al.

PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
PHENOTYPIC DIFFERENCES IN INFLAMMATORY BOWEL DISEASE BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA

Xavier Calvet Calvo  et al.

SAFETY AND LONG-TERM PERSISTENCE OF BIOLOGICAL TREATMENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. DIFFERENCES BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
SAFETY AND LONG-TERM PERSISTENCE OF BIOLOGICAL TREATMENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. DIFFERENCES BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA

Xavier Calvet Calvo  et al.

Item 1 - 15 / 15
1